Microbix Biosystems Inc.
Microbix Biosystems Inc. (MBX.TO) Financial Performance & Income Statement Overview
Review Microbix Biosystems Inc. (MBX.TO) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Microbix Biosystems Inc. (MBX.TO) Income Statement & Financial Overview
Analyze Microbix Biosystems Inc.’s MBX.TO earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $5.32M | $6.04M | $6.29M | $5.06M |
| Cost of Revenue | $2.16M | $2.29M | $2.84M | $2.31M |
| Gross Profit | $3.17M | $3.75M | $3.45M | $2.75M |
| Gross Profit Ratio | $0.60 | $0.62 | $0.55 | $0.54 |
| R&D Expenses | $509737.00 | $599602.00 | $582462.00 | $562820.00 |
| SG&A Expenses | $2.48M | $2.18M | $1.67M | $2.02M |
| Operating Expenses | $2.99M | $2.78M | $3.45M | $2.58M |
| Total Costs & Expenses | $5.15M | $5.07M | $5.58M | $4.89M |
| Interest Income | $93263.00 | $117938.00 | $275725.00 | $145575.00 |
| Interest Expense | $251225.00 | $231067.00 | $228985.00 | $230773.00 |
| Depreciation & Amortization | $428043.00 | $434942.00 | $399573.00 | $426655.00 |
| EBITDA | $699932.00 | $1.52M | $1.22M | $904174.00 |
| EBITDA Ratio | $0.13 | $0.25 | $0.19 | $0.18 |
| Operating Income | $178625.00 | $970091.00 | $0.00 | $165314.00 |
| Operating Income Ratio | $0.03 | $0.16 | $0.00 | $0.03 |
| Other Income/Expenses (Net) | -$157961.00 | -$113129.00 | $590887.00 | $81432.00 |
| Income Before Tax | $20664.00 | $856962.00 | $590887.00 | $246746.00 |
| Income Before Tax Ratio | $0.004 | $0.14 | $0.09 | $0.05 |
| Income Tax Expense | $0.00 | $0.00 | $150563.00 | $0.00 |
| Net Income | $20664.00 | $856962.00 | $440324.00 | $246746.00 |
| Net Income Ratio | $0.004 | $0.14 | $0.07 | $0.05 |
| EPS | $0.00 | $0.006 | $0.003 | $0.002 |
| Diluted EPS | $0.00 | $0.006 | $0.003 | $0.002 |
| Weighted Avg Shares Outstanding | $139.85M | $134.91M | $135.81M | $136.84M |
| Weighted Avg Shares Outstanding (Diluted) | $140.62M | $135.55M | $136.52M | $137.63M |
The company's financials show resilient growth, with revenue advancing from $5.06M in Q3 2024 to $5.32M in Q2 2025. Gross profit remained healthy with margins at 60% in Q2 2025 compared to 54% in Q3 2024. Operating income hit $178625.00 last quarter, sustaining a consistent 3% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $699932.00. Net income dropped to $20664.00, while earnings per share reached $0.00. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan